CD28
CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and provides a critical co-stimulatory signal. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. CD28 interacts with the CD80 dimer with relatively high affinity and the CD86 monomer with lower affinity, mediating T cell co-stimulation in conjunction with T cell receptor (TCR) signals. CD28 drives critical intracellular biochemical events including unique phosphorylation and transcriptional signaling, metabolism, and the production of key cytokines, chemokines, and survival signals that are essential for long-term expansion and differentiation of T cells. Most importantly, treatment of mice with a soluble CD28 antagonist induced antigen-specific tolerance that prevented the progression of autoimmune diseases and organ graft rejection.
All Product Categories
-
CD28 Related Products (49)
Related Products (49)
-
Antibodies (8)
-
Tiragolumab
0 ImagesSynonyms: MTIG-7192A; RG-6058Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.
-
Lulizumab
0 ImagesCat. No.: HY-P99302CAS No.: 2235419-62-0Synonyms: BMS-931699 AntibodyLulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft.
-
Galiximab
0 ImagesSynonyms: IDEC 114; Anti-Human CD80 Recombinant AntibodyGaliximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors.
-
Radanstobart
0 ImagesSynonyms: HFB-200603
-
Anti-Mouse BTLA/CD272 Antibody (PK18.6)
0 ImagesCat. No.: HY-P991833Anti-Mouse BTLA/CD272 Antibody (PK18.6) reacts with mouse B- and T-lymphocyte attenuator (BTLA). BTLA is an Ig superfamily member. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).
-
Anti-CD28 Antibody (9.3)
0 ImagesCat. No.: HY-P990865Purity: 99%
-
Tifcemalimab
0 ImagesCat. No.: HY-P99961CAS No.: 2236068-83-8Synonyms: JS004; IcatolimabTifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer.
-
FR104
0 ImagesCat. No.: HY-P990587
-
GSK699
0 ImagesGSK699 is a KAT2A/B/PCAF/GCN5 PROTAC degrader. GSK699 induces proteasome-dependent degradation of KAT2A, KAT2B, PCAF and GCN5, regulates the histone acetyltransferase activity of the SAGA complex, and reduces the level of histone H3K9ac. GSK699 inhibits the growth of neuroblastoma, acute myeloid leukemia and small cell lung cancer cells. GSK699 reduces the production of inflammatory cytokines and chemokines, and impairs LPS-stimulated immune cell responses. GSK699 is applicable to research related to acute myeloid leukemia, small cell lung cancer, neuroblastoma and inflammatory diseases.
-
Acazicolcept
0 ImagesSynonyms: ALPN-101Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities.
-
Reltecimod
0 ImagesSynonyms: AB-103Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).
-
B7/CD28 interaction inhibitor 1
0 ImagesB7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM.
-
CD80-IN-3
0 ImagesCD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC50 of 630 nM and a Kd of 125 nM.
-
Anti-CD80 Antibody (TKMF5)
0 ImagesCat. No.: HY-P991907
-
Venanprubart
0 ImagesSynonyms: LY-3361237
-
KY-1044
0 ImagesSynonyms: Alomfilimab; SAR 445256KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response.
